34.07
前日終値:
$34.62
開ける:
$33.3
24時間の取引高:
2.31M
Relative Volume:
0.82
時価総額:
$6.48B
収益:
$217.77M
当期純損益:
$-438.86M
株価収益率:
-14.14
EPS:
-2.41
ネットキャッシュフロー:
$-456.33M
1週間 パフォーマンス:
-6.40%
1か月 パフォーマンス:
+3.21%
6か月 パフォーマンス:
+32.93%
1年 パフォーマンス:
+16.56%
Bridgebio Pharma Inc Stock (BBIO) Company Profile
BBIO を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
BBIO
Bridgebio Pharma Inc
|
34.07 | 6.48B | 217.77M | -438.86M | -456.33M | -2.41 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
484.01 | 124.29B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
610.64 | 66.76B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
590.06 | 35.99B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
262.16 | 33.93B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
264.32 | 28.47B | 3.81B | -644.79M | -669.77M | -6.24 |
Bridgebio Pharma Inc Stock (BBIO) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2025-03-31 | 開始されました | Redburn Atlantic | Buy |
2024-10-16 | 開始されました | Scotiabank | Sector Outperform |
2024-10-03 | 開始されました | Oppenheimer | Perform |
2024-09-04 | 開始されました | Piper Sandler | Overweight |
2024-03-21 | 再開されました | Raymond James | Outperform |
2024-01-31 | 開始されました | BMO Capital Markets | Market Perform |
2023-12-08 | 開始されました | Wells Fargo | Overweight |
2023-11-07 | 開始されました | Citigroup | Buy |
2023-10-24 | 開始されました | Cantor Fitzgerald | Overweight |
2023-07-18 | ダウングレード | Jefferies | Buy → Hold |
2023-04-19 | 開始されました | Evercore ISI | Outperform |
2023-02-06 | 開始されました | Cowen | Outperform |
2021-12-27 | 繰り返されました | Mizuho | Buy |
2021-12-27 | 繰り返されました | SVB Leerink | Outperform |
2021-09-10 | アップグレード | BofA Securities | Neutral → Buy |
2021-05-21 | 開始されました | UBS | Buy |
2021-03-22 | 繰り返されました | Goldman | Buy |
2021-02-22 | 再開されました | JP Morgan | Overweight |
2021-02-09 | 再開されました | Goldman | Buy |
2021-01-11 | 繰り返されました | H.C. Wainwright | Buy |
2020-12-10 | 繰り返されました | H.C. Wainwright | Buy |
2020-06-25 | 開始されました | BofA/Merrill | Neutral |
2020-05-19 | 開始されました | BTIG Research | Buy |
2020-04-13 | 開始されました | H.C. Wainwright | Buy |
2020-02-19 | 開始されました | Mizuho | Buy |
2019-07-26 | 開始されました | Raymond James | Outperform |
2019-07-22 | 開始されました | BMO Capital Markets | Outperform |
2019-07-22 | 開始されました | Goldman | Buy |
2019-07-22 | 開始されました | JP Morgan | Overweight |
2019-07-22 | 開始されました | Jefferies | Buy |
2019-07-22 | 開始されました | Piper Jaffray | Overweight |
2019-07-22 | 開始されました | SVB Leerink | Outperform |
すべてを表示
Bridgebio Pharma Inc (BBIO) 最新ニュース
BridgeBio Pharma director Andrea Ellis sells $1.02 million in stock - Investing.com
Redburn Atlantic Initiates Coverage of BridgeBio Pharma (MUN:2CL) with Buy Recommendation - Nasdaq
Raymond James maintains $57 target on BridgeBio stock By Investing.com - Investing.com Canada
Revolutionary Dual-State KRAS Inhibitor Enters Clinical Trials for Advanced Cancer Treatment - Stock Titan
Acoramidis shows promise in ATTR-CM Phase 3 trial By Investing.com - Investing.com South Africa
Redburn Atlantic Initiates Coverage of BridgeBio Pharma (BBIO) with Buy Recommendation - Nasdaq
BridgeBio Pharma Says Acoramidis Improves Outcomes in Phase 3 ATTR-CM Trial - MarketScreener
Acoramidis shows promise in ATTR-CM Phase 3 trial - Investing.com
Breakthrough: New ATTR-CM Drug Shows Dramatic 59% Risk Reduction in Phase 3 Trial - Stock Titan
Redburn Atlantic Initiates BridgeBio Pharma at Buy With $50 Price Target - Marketscreener.com
Redburn-Atlantic sets $50 target for BridgeBio stock with Buy rating - Investing.com India
Pictet Asset Management Holding SA Sells 995,585 Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO) - MarketBeat
Cytokinetics, Madrigal, and BridgeBio Emerge as Potential Pharma Takeover Targets - GuruFocus
Why BridgeBio Pharma (BBIO) Is Among the Best Mid Cap Biotech Stocks to Buy - Insider Monkey
(BBIO) Technical Data - news.stocktradersdaily.com
Genmab and BridgeBio Pharma announce Japan approval for their treatments - MSN
BridgeBio Pharma CEO sells $2.76 million in stock By Investing.com - Investing.com Canada
BridgeBio Pharma CEO sells $2.76 million in stock - Investing.com India
Japan approves new ATTR-CM treatment Beyonttra By Investing.com - Investing.com South Africa
Japan Approves BridgeBio Pharma-AstraZeneca Partnered Rare Heart Disease Drug - Benzinga
BridgeBio’s Beyonttra approved in Japan - The Pharma Letter
BridgeBio Pharma Says Beyonttra Approved in Japan to Treat Heart Condition - Marketscreener.com
BridgeBio Announces Approval Of Beyonttra In Japan; To Receive $30 Mln Milestone Payment - Nasdaq
Beyonttra(TM) (Acoramidis), The First Near-Complete TTR Stabilizer (>=90%), Approved in Japan To Treat ATTR-CM - MarketScreener
Japan approves new ATTR-CM treatment Beyonttra - Investing.com
Game-Changing Heart Disease Drug Beyonttra Achieves 42% Mortality Reduction in Japan - Stock Titan
BridgeBio to Present Cardiovascular Outcomes Data in Patients with Variant and Wild-type Transthyretin Amyloid Cardiomyopathy (ATTR-CM) from the ATTRibute-CM Study at the ACC Annual Scientific Sessions - The Manila Times
BridgeBio Pharma to Present Cardiovascular Outcomes Data from ATTRibute-CM Study at ACC Annual Scientific Sessions 2025 - Nasdaq
Achondroplasia Treatment Market Size in 7MM is expected to grow - openPR
Alnylam challenges Pfizer and BridgeBio with FDA nod for ATTR-CM drug - MSN
BridgeBio Pharma Inc (BBIO) Announces Equity Grants to New Employees - GuruFocus.com
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Bridgebio Pharma reports inducement grants under Nasdaq listing rule 5635(C)(4) -March 21, 2025 at 04:05 pm EDT - Marketscreener.com
Alnylam Drug Approval Brings Cardiomyopathy Competition to Pfizer, BridgeBio Pharma - MedCity News
Alnylam prices heart drug at premium to rivals - BioPharma Dive
Alnylam Jumps As A New Approval Sets Up Its Next Battle With Pfizer, BridgeBio - MSN
NYSE Content advisory: Pre-Market update + Stocks try for weekly gains - The Globe and Mail
BridgeBio, Editas finance chiefs depart; Former FDA No. 2 joins Recursion’s board - Endpoints News
Alnylam Joins Competitive ATTR-CM Market With Amvuttra Approval - News & Insights
Achondroplasia Market on Track for Major Expansion by 2034, - openPR
UBS Adjusts Price Target on BridgeBio Pharma to $65 From $62, Maintains Buy Rating - Marketscreener.com
Trend Tracker for (BBIO) - Stock Traders Daily
BridgeBio Announces CFO Succession - The Manila Times
BridgeBio Pharma Appoints New President and CFO - TipRanks
BridgeBio Pharma announces CFO succession -March 17, 2025 at 04:30 pm EDT - Marketscreener.com
BridgeBio Pharma Names New CFO -March 17, 2025 at 04:21 pm EDT - Marketscreener.com
BridgeBio Promotes Internal Leader to CFO Role, Ensuring Strategic Continuity - StockTitan
BridgeBio Pharma Names Thomas Trimarch as New Finance Chief - MarketWatch
Lobbying Update: $30,000 of BRIDGEBIO PHARMA INC. lobbying was just disclosed - Nasdaq
BridgeBio Pharma’s SWOT analysis: innovative pipeline drives stock potential - Investing.com
BridgeBio Pharma director Hannah Valantine sells $419,499 in stock By Investing.com - Investing.com South Africa
Bridgebio Pharma Inc (BBIO) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):